Results 271 to 280 of about 219,205 (349)

Novel Immunotherapeutic Strategies for Castration-Resistant Prostate Cancer: Mechanisms and Clinical Advances. [PDF]

Curr Issues Mol Biol
Xia X, Xia Z, Yu L.
europepmc   +1 more source

Conkazal‐M1 from the MKAVA family of conotoxins: A dual‐function protease inhibitor and neuroactive peptide

Protein Science, Volume 35, Issue 5, May 2026.
Abstract Marine cone snails produce a diverse array of bioactive peptides, known as conotoxins, in their venom. Given their high target potency and specificity, conotoxins are attractive compounds for the development of precision research tools and pharmacological agents.
Celeste M. Hackney, Thomas Lund Koch, Nicklas Lund Ryding, Aymeric Rogalski, Kevin Chase, Matías Leonel Giglio, Samuel S. Espino, Zildjian G. Acyatan, Maren Watkins, Baldomero M. Olivera, Helena Safavi‐Hemami, Kaare Teilum, Lars Ellgaard   +12 more
wiley   +1 more source

Prognostic Factors of Castration-Resistant Prostate Cancer Among Patients With Localized Prostate Cancer Who Underwent Robot-Assisted Radical Prostatectomy in a Retrospective Multicenter Japanese Cohort (MSUG94). [PDF]

Int J Urol
Sasaki T, Igarashi A, Ebara S, Tatenuma T, Ikehata Y, Nakayama A, Kawase M, Toide M, Yoneda T, Sakaguchi K, Teishima J, Makiyama K, Kitamura H, Saito K, Koie T, Koga F, Urakami S, Yamasaki T, Inoue T.   +18 more
europepmc   +1 more source

Evaluation of Loss of the Y Chromosome in Peripheral Blood as a Biomarker for Prostate Cancer

The Prostate, Volume 86, Issue 6, Page 665-675, May 2026.
ABSTRACT Background Prostate cancer (PCa) is the most common malignant tumor in men, but the widely used prostate‐specific antigen (PSA) test has limited diagnostic accuracy. Research proposes that the loss of the Y chromosome (LOY) may affect the occurrence and development of prostate cancer, aiming to assess its potential as a diagnostic biomarker to
Jun Lu, Yan Lu, Takuro Kobayashi, Tsuyoshi Hachiya, Haruhiko Wakita, Yiming Jin, Yasunari Tanaka, Yoshihiro Ikehata, Masayoshi Nagata, Hisamitsu Ide, Shigeo Horie   +10 more
wiley   +1 more source

A novel cancer gene therapy achieving reciprocal regulation of PTEN and PARP1 expression. [PDF]

Mol Ther Oncol
Otsuka Y, Watanabe T, Kudo M.
europepmc   +1 more source

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation

The Prostate, Volume 86, Issue 6, Page 727-731, May 2026.
ABSTRACT Background Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).
Mayuko Kanayama, Violet A. Daniels, Marta Gielzak, Alex Brame, Misop Han, Li Jia, Jianfeng Xu, Tamara L. Lotan, Mario A. Eisenberger, Catherine H. Marshall, Patrick C. Walsh, William B. Isaacs, Jun Luo   +12 more
wiley   +1 more source

FDA expanded approval of Pluvicto (Lutetium-177 vipivotide tetraxetan) in metastatic castration-sensitive prostate cancer. [PDF]

Ann Med Surg (Lond)
Saqib M, Arshad B, Imran SB, Haider E.
europepmc   +1 more source

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis

The Prostate, Volume 86, Issue 6, Page 689-696, May 2026.
ABSTRACT Background In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune ...
Tomoya Hatayama, Yohei Sekino, Go Kobayashi, Kazuma Yukihiro, Yoshinori Nakano, Shinsaku Tasaka, Naofumi Nomura, Yuki Kohada, Kenshiro Takemoto, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +16 more
wiley   +1 more source